Three toolmakers reported in the first week of November, and all three described instrument demand getting better, not worse.
The Big Picture: Waters, Bruker and Mettler-Toledo all reported in the first week of November, and all three said instrument buying is getting better. Waters and Mettler raised their outlooks. Deals kept closing, and a Senate draft bill would keep NIH overhead rules as they are. The federal stopgap still runs out Dec 11.
The Big Story: Lab instrument orders pick up at Waters, Mettler and Bruker
Waters went first on Nov 3. Revenue was $1.767 billion, including $896 million from the BD Biosciences and Diagnostic Solutions businesses it now owns. Its legacy business grew 10% in constant currency, with instruments up 10% and chemistry consumables up 12% in the Analytical Sciences division. Waters raised full year revenue guidance to $6.479 billion to $6.497 billion.
Bruker followed on Nov 4. Revenue was $874.0 million, up 1.6%, with organic growth of only 0.7%. The better number for reps was bookings: its Scientific Instruments group posted a book-to-bill above one for the fifth quarter running. CEO Frank Laukien said demand is strengthening in most end markets, and in the third quarter also in US academia.
Mettler-Toledo reported Nov 5. Sales were $1.094 billion, up 6%. Asia and the rest of the world grew 14% in local currency, the Americas 3% and Europe 2%. Mettler raised its 2026 earnings outlook and guided to about 5% local currency growth in 2027.
Who it affects: Reps selling LC-MS, analytical systems and balances, and the consumables reps who sell into that installed base.
Why it matters: Three vendors with different customer mixes say labs are spending on instruments again, with drug testing, environmental testing and US academia named as growth sources. Expect competitors to chase the same replacement deals before year end.
Sources: Waters release, Bruker release, Mettler-Toledo release
New here? Get this in your inbox.
A free five minute brief every Tuesday morning, written for the people who sell into this industry.
Get it free every TuesdayNIH money: a Senate draft and a Dec 11 deadline
Senate appropriators have posted a draft fiscal 2027 Labor-HHS bill, with text dated Nov 15. It would fund the National Cancer Institute at $7.51 billion. Section 224 keeps today's indirect cost rules for NIH grants and blocks work on a new overhead formula. It is a draft, not law.
Until a full year bill passes, NIH runs on a continuing resolution through Dec 11. Under NIH's notice, institutes may issue continuing grants below the amount on the last Notice of Award, with any increase only after fiscal 2027 money is enacted.
Why it matters: Academic labs on trimmed continuation awards will hold capital purchases until the money is certain. The overhead language helps core facilities, but nothing changes until Congress votes.
Sources: Senate draft bill, NIH notice NOT-OD-26-131
Earnings Watch
- Waters (Nov 3): 2026 organic constant currency growth guidance raised to 9.1% to 9.7%.
- Bruker (Nov 4): 2026 organic growth guidance of 1% to 2% reconfirmed.
- Mettler-Toledo (Nov 5): 2026 adjusted EPS guidance raised to $47.70 to $47.90.
Two raises and one reconfirmation. Bruker and Mettler also gave early reads on 2027.
Sources: company releases linked above.
Deal Watch
Waters buys MOBILion. Waters acquired MOBILion Systems, maker of SLIM ion mobility technology, on Nov 3 to push into proteomics. Waters sizes LC-MS proteomics at $2 billion, growing at a high single digit rate. Terms were not disclosed. Source
Agilent closes Proscia. Agilent completed its purchase of digital pathology software company Proscia for $240 million in cash, plus up to $30 million in milestones. Source
Biomark Scientific is born. ARCHIMED closed its purchase of Standard BioTools' microfluidics business on Nov 3. It now runs independently as Biomark Scientific, with the same team. Source
Straight quarters with a book-to-bill above one at Bruker Scientific Instruments: orders are running ahead of shipments. Source
Talk Track
Three questions to ask your lab accounts this week:
- Which instruments did you push to next year, and could any of them move up before your budget resets?
- If your NIH continuation comes in below the award amount, what gets cut first: equipment, service contracts or reagents?
- Is anyone on your team asking about proteomics or digital pathology for 2027?
The vendors say demand is back. Find out if your accounts agree.
Jobs
- Our picks this week. We could confirm three new roles, so all of them are here.
- Sr Territory Account Manager, NC West and SC, Illumina (North Carolina, remote). Owns the Illumina territory across western North Carolina and South Carolina. Posted Nov 11. Apply
- Global Account Manager, Revvity Signals, Revvity (California, remote). Sells scientific R&D software into large strategic accounts. Base pay $130,000 to $140,000 listed. Posted Nov 4. Apply
- Field Applications Scientist 2, Illumina (Colorado, remote). The technical partner on the sales team, running customer evaluations. Posted Nov 13. Apply
- Hiring? Send us the role and we'll consider it for next week.
What We're Watching
- Dec 11: the federal stopgap expires. Watch for another continuing resolution or a full year bill.
- Bruker's fourth quarter: it kept 1% to 2% organic growth for 2026 after 0.7% in the third quarter, so year end has to carry more.
We're looking for industry advisors and contributors
We want a few people who do this work behind the brief: reps, application scientists, sales managers and lab buyers. Send a tip, give an issue a quick read before it goes out, or write a short piece now and then.
You get credit by name in the brief. That is the whole offer.
Raise your hand here, with a line about your role.
Forward this to someone on your team who'd use it.
The Editorial Team
Reading this on the web?
A free five minute brief every Tuesday morning, written for the people who sell into this industry.
Get it free every TuesdayLife Science Tools Brief is an independent publication by its editorial team. Nothing here is investment advice.